HK Stock Market Move | KINTOR PHARMA-B(09939) rises more than 10%, KX-826 Phase III data unveils at WCHR 2026.
Kaituo Pharmaceutical-B (09939) surged over 10%, as of the time of writing, it was up by 10.43% to 2.54 Hong Kong dollars, with a trading volume of 39.679 million Hong Kong dollars.
KINTOR PHARMA-B (09939) rose more than 10%, reaching a 10.43% increase at the time of publication, trading at 2.54 Hong Kong dollars with a transaction value of 3.9679 million Hong Kong dollars.
On the news front, on June 1st, Kantor Pharma announced that its independently developed and potentially first-of-its-kind KX-826 was presented at the 14th World Congress for Hair Research (WCHR 2026) held in Seoul, South Korea from May 28 to 31. The presentation included two important clinical research data: the Phase III clinical trial data for treating androgenic alopecia (AGA or hair loss) in Chinese adult males. The overall results showed that KX-826 demonstrated excellent effectiveness and safety in treating hair loss patients.
Additionally, clinical observation trial data on the joint treatment of male hair loss in adult Chinese men with minoxidil was also presented. The clinical observation trial, led by Professor Jiang Leiwei, provides sufficient evidence for future Phase III clinical trials on the joint therapy of KX-826 with minoxidil. The company stated that it is actively pursuing the market approval for KX-826. Once approved, KX-826 is expected to become a first-of-its-kind topical innovating drug in its class.
Related Articles
HK Stock Market Move | CIRRUS (02507) increases by over 4% again, impressive delivery growth expected in the next quarter despite a high base.
HK Stock Market Move | Chinese-funded securities firms continue to rise, with star projects such as Changxin concentrated on meeting. It is expected that securities firms' second-quarter performance will continue to show high growth.
From pure photovoltaics towards "integrated light storage": Credit Suisse is bullish on Nextpower's acquisition of Prevalon, maintaining an "outperform" rating.
HK Stock Market Move | CIRRUS (02507) increases by over 4% again, impressive delivery growth expected in the next quarter despite a high base.
HK Stock Market Move | Chinese-funded securities firms continue to rise, with star projects such as Changxin concentrated on meeting. It is expected that securities firms' second-quarter performance will continue to show high growth.
From pure photovoltaics towards "integrated light storage": Credit Suisse is bullish on Nextpower's acquisition of Prevalon, maintaining an "outperform" rating.
